Cognitive Effects of Immunomodulatory Drugs in MS

Sharon Lynch, MD96 enrolled

Overview

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Multiple Sclerosis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of RRMS for at least one year, * Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif), * Visual Acuity is 20/50 or better, * patient has four color vision, * Must have at least a high school education Exclusion Criteria: * History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS, * currently taking immunosuppressant medication, * resides greater than 200 miles from the study site

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.